Heart Failure

The FDA approval of sotagliflozin (Inpefa) for the treatment of heart failure was announced by Lexicon Pharmaceuticals on May 26, 2023.

A posthoc analysis of the EMPEROR-Preserved trial suggested empagliflozin decreased the risk of heart failure hospitalization or cardiovascular death, regardless of background diuretic status.

Ahead of the May 27, 2023 PDUFA date, the HCPLive Cardiology editorial team spoke to a group of cardiologists to capture their perspective of the potential role of sotagliflozin.

An analysis of cost-effectiveness using data from SOLOIST-WHF provides insight into the varying cost-effectiveness of the agent as a treatment for worsening heart failure.

Muthiah Vaduganathan, MD, MPH, offers perspective on data from the PARAGLIDE-HF trial as well as a pooled analysis of data from the PARAGLIDE-HF and PARAGON-HF trials.

Presented at ESC HFA 2023, results of PARAGLIDE-HF detail the effects of sacubitril/valsartan on NT-proBNP and multiple clinical outcomes, relative to valsartan alone, in patients with HFmrEF or HFpEF.

Announced just more than a year after AstraZeneca announced topline results, the FDA has approved a label expansion to include reducing cardiovascular death and HF hospitalizations for dapagliflozin based on results of the phase 3 DELIVER trial.

An analysis of the National Inpatient Sample offers a deep dive into the risk of adverse outcomes associated with presence of polymyositis or dermatomyositis among patients with congestive heart failure.

Each month, our editorial staff compiles a recap of the top news in cardiology from the past month. Our April 2023 month in review features new data and documents related to heart failure management, recaps and forecasts of top regulatory decisions, and other top news!

Leveraging data from the UK Biobank study, a new study offers insight into the risk of new-onset heart failure based on female reproductive risk factors among a cohort more than 220,000 women.

A prespecified analysis of the DELIVER trial provides insight into the effects of dapagliflozin use on total heart failure events in patients with mildly reduced or preserved ejection fraction.

On April 19, 2023, an expert clinical decision pathway and scientific statement were published simultaneously in JACC. Both of these documents were aimed at providing an overview of heart failure with preserved ejection fraction, including diagnosis and management, based on contemporary evidence.

An analysis of hospitals in the Get With The Guidelines-HF program provides an overview of quality of care for patients treated at hospitals with a high proportion of Black patients relative to other hospitals within the program.

Using data from 4 major phase 3 trials and the Global Burden of Disease Report, investigators detail the potential impact of optimal prescription of SGLT2 inhibitors in heart failure by estimating the number of worsening heart failure events and cardiovascular deaths prevented or postponed as a result of uptake.

A systematic review and meta-analysis detail the unadjusted odds of developing chemotherapy-related cardiotoxicity among patients who are Black or of African ancestry relative to their White counterparts.

From a novel topical gene therapy to a multi-pathway targeting HF drug, the second quarter of 2023 is laden with interesting regulatory decisions.

An analysis of data from patients in the DELIVER and DAPA-HF trials in the Americas provides an overview of the benefits of dapagliflozin in Black patients relative to White patients.

This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.

Released on March 21, the new scientific statement suggests supervised exercise training is safe and may offer substantial improvement in exercise capacity and quality of life, even more than medications, for many patients with heart failure.

Gregg W. Stone, MD, discussed the 5-year findings of the COAPT trial and provided insight into the benefit of the transcatheter procedure in high-risk patients with heart failure.

In an interview at ACC 2023, Safia Chatur, MD provided insight into the analysis of the PARADIGM-HF and PARAGON-HF trials, suggesting early eGFR changes should not deter continuation of sacubitril/valsartan.

At ACC 2023, results from the RAPID-HF trial reported atrial pacing was ineffective at improving exercise capacity in patients with HFpEF and chronotropic incompetence.

Data from cohort 4 in REDWOOD-HCM provides the first insight into the effects of aficamten in a cohort of patients with non-obstructive hypertrophic cardiomyopathy.

In an interview at ACC 2023, Ankeet Bhatt, MD, describes how virtual care team represents an effective and scalable approach to improve therapeutic optimization across a health system.

Implantation of a pacemaker to enhance exercise heart rate did not improve exercise capacity, symptoms, or exercise cardiac output in patients with HFpEF and chronotropic incompetence in the RAPID-HF trial.

Clyde Yancy, MD, offers insight into his keynote address and the importance of both recognizing and addressing inequities within heart failure management.

In a Q&A at ACC 2023, Drs. Alexandra Murphy and Birgit Vogel of Mount Sinai discuss sex-specific predictors of MACE and the need for individualization of care to achieve equity in cardiovascular health.

Results from the STOP-CA trial suggest patients taking atorvastatin for one year were significantly less likely to show evidence of heart dysfunction than those who took a placebo.

A new meta-analysis of 9 randomized trials suggests restricting dietary sodium intake to levels below 2.3 grams per day may increase the risk of death in patients with heart failure.

Cytokinetics announced the CRL on Tuesday, as well as their intentions to forego any future clinical trials for the agent while focusing on the development of aficamten.